Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have been given an average rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $41.75.

Several research firms recently weighed in on VRDN. Wall Street Zen upgraded shares of Viridian Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. The Goldman Sachs Group reiterated a “buy” rating and issued a $40.00 price objective on shares of Viridian Therapeutics in a research report on Thursday, November 6th. Truist Financial set a $41.00 price objective on Viridian Therapeutics in a report on Monday, November 24th. Wedbush upped their target price on Viridian Therapeutics from $42.00 to $47.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $61.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, November 4th.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc bought 454,545 shares of the firm’s stock in a transaction dated Thursday, October 23rd. The shares were acquired at an average cost of $22.00 per share, for a total transaction of $9,999,990.00. Following the transaction, the director owned 3,914,458 shares in the company, valued at approximately $86,118,076. The trade was a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Jennifer Tousignant sold 2,272 shares of the company’s stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total transaction of $70,795.52. The SEC filing for this sale provides additional information. 0.65% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Viridian Therapeutics

Several large investors have recently modified their holdings of VRDN. Aster Capital Management DIFC Ltd bought a new position in shares of Viridian Therapeutics during the 3rd quarter worth approximately $35,000. Farther Finance Advisors LLC grew its position in Viridian Therapeutics by 332.1% in the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock valued at $42,000 after acquiring an additional 1,491 shares during the period. Bessemer Group Inc. raised its stake in Viridian Therapeutics by 947.7% during the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock worth $45,000 after acquiring an additional 1,886 shares in the last quarter. Larson Financial Group LLC bought a new position in shares of Viridian Therapeutics during the third quarter valued at $52,000. Finally, US Bancorp DE lifted its holdings in shares of Viridian Therapeutics by 23.2% during the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after acquiring an additional 463 shares during the period.

Viridian Therapeutics Trading Down 1.4%

Shares of VRDN stock opened at $30.68 on Monday. The firm has a market capitalization of $2.93 billion, a P/E ratio of -10.16 and a beta of 0.90. Viridian Therapeutics has a 1 year low of $9.90 and a 1 year high of $34.04. The firm’s fifty day simple moving average is $29.73 and its 200 day simple moving average is $22.45. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.07.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.48. Viridian Therapeutics had a negative net margin of 426.58% and a negative return on equity of 78.50%. The firm had revenue of $70.57 million during the quarter, compared to the consensus estimate of $16.21 million. The firm’s revenue for the quarter was up 81993.0% on a year-over-year basis. As a group, sell-side analysts predict that Viridian Therapeutics will post -4.03 EPS for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.